1. Academic Validation
  2. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor

  • J Med Chem. 2008 Aug 14;51(15):4632-40. doi: 10.1021/jm800566m.
Philip A Harris 1 Amogh Boloor Mui Cheung Rakesh Kumar Renae M Crosby Ronda G Davis-Ward Andrea H Epperly Kevin W Hinkle Robert N Hunter 3rd Jennifer H Johnson Victoria B Knick Christopher P Laudeman Deirdre K Luttrell Robert A Mook Robert T Nolte Sharon K Rudolph Jerzy R Szewczyk Anne T Truesdale James M Veal Liping Wang Jeffrey A Stafford
Affiliations

Affiliation

  • 1 GlaxoSmithKline, Five Moore Drive, Research Triangle Park, North Carolina 27709, USA. philip.a.harris@gsk.com
Abstract

Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for Cancer therapy. We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N(4)-(2,3-dimethyl-2H-indazol-6-yl)-N(4)-methyl-N(2)-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clinical development for renal-cell Cancer and other solid tumors.

Figures
Products